Hahn Mark W's Form 4 filing
Verona Pharma plc (VRNA) · filed Aug 11, 2022
- Accession no.
- 0001104659-22-089565
- Filed
- Aug 11, 2022
- Trade date
- Aug 9, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $1.05M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hahn Mark WCIK 0001408502 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 9, 2022 | Ordinary Shares | SSaleDisposed | −600,000 | $1.75F3 | −$1,050,000 | 14,313,496 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported represents the sale price of the ADSs divided by eight (8).
Referenced by the price of 1 transaction in Table I.